A man with dyslipidemia: to treat or not to treat?
AbstractMr R is a 43 year-old Indian man. He has hypertension for the past one year, and was started on an angiotensin II receptor blocker recently (his latest BP is 130/80 mm Hg). He is a non-smoker and is not known to have diabetes. His BMI is 25.4 kg/m2. His latest fasting glucose is 5.1 mmol/L. Mr R. does not consume alcohol and does not exercise regularly. His father died of a heart attack at the age of 55. His grandfather had hypertension and diabetes. (copied from article)
Ong HT. The statin studies: from targeting hypercholesterolemia to targeting the high-risk patient. QJM. 2005 Aug;98(8):599-614.
Grundy SM, Cleeman JI, Merz CNB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol education Program Adult Treatment Panel III Guidelines. Circulation. 2004 Jul 13;110(2):227-39.
Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality. A systematic review. Arch Intern Med. 2005 Apr 11;165(7):725-30.
Keech A, Simes RJ, Barter P, for the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615-22.